Therapeutic Areas

Pearl is developing product candidates for globally prevalent chronic respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma and rhinosinusitis. The Company’s lead products are being investigated for the treatment of patients with COPD.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) refers to a group of diseases including emphysema and chronic bronchitis that cause airflow limitation, shortness of breath, chest tightness, and other breathing-related symptoms. In the United States, smoking is a key factor in the development and progression of COPD; but exposure to pollutants, genetic factors, and respiratory infections also play a role.1

Additional Facts about COPD

  • COPD is the 3rd leading cause of death in the United States2
  • More than 12 million people have a diagnosis of COPD and an additional 12 million likely have the disease but remain undiagnosed2
  • Total deaths from COPD are projected to increase by more than 30% in the next 10 years3
  • COPD is not curable, but treatment can slow the progress of the disease3
  • COPD most often occurs in current or former smokers, although as many as one out of six people with COPD never smoked2

Bronchodilator medications are central to symptom management in COPD. (GOLD, 2009)

  • Bronchodilators are prescribed on an as-needed or regular basis to prevent or reduce symptoms4
  • Long-acting inhaled bronchodilators are recommended for patients with significant symptoms, but low risk of exacerbations4
  • Combining bronchodilators of different pharmacological classes has been shown to improve efficacy and may decrease the risk of side effects compared to increasing the dose of a single bronchodilator5

In accordance with treatment recommendations as outlined in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and other international guidelines, Pearl is developing a portfolio of inhaled products with a specific focus on the development of combination products intended to optimize the treatment of COPD. Pearl’s products are not approved by the Food and Drug Administration and are not available for commercial distribution in the United States.

References:

1 “Chronic Obstructive Pulmonary Disease Surveillance — United States, 1971–2000.” MMWR 2002; 51(SS-6):1–16. Retrieved from CDC.gov, May 14, 2013.

2 “COPD: Are You at Risk?” National Heart Lung and Blood Institute. Retrieved May 14, 2013.

3 “Chronic obstructive pulmonary disease (COPD) Fact sheet” N°315, November 2012. Retrieved from WHO.org, May 14, 2013.

4 “Global Strategy for the Diagnosis, Management and Prevention of COPD,” Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Retrieved from: www.goldcopd.org, May 14, 2013.

5 van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyper-inflation in patients with COPD. Chest. 2006; 129:509–17.